Emgality and Thinking abnormal - a phase IV clinical study of FDA data

Summary:

Thinking abnormal is reported as a side effect among people who take Emgality (galcanezumab-gnlm), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Relpax, and have Migraine.

The phase IV clinical study analyzes which people have Thinking abnormal when taking Emgality. It is created by eHealthMe based on reports of 24,623 people who have side effects when taking Emgality from the FDA, and is updated regularly.

What is Emgality?

Emgality has active ingredients of galcanezumab-gnlm. eHealthMe is studying from 24,702 Emgality users. Check the latest studies of Emgality.

What is Thinking abnormal?

Thinking abnormal is found to be associated with 1,087 drugs and 1,180 conditions by eHealthMe. Check the latest studies of Thinking abnormal.

On Apr, 29, 2026

24,623 people reported to have side effects when taking Emgality.
Among them, 32 people (0.13%) have Thinking abnormal.

Among these 32 people:

How long have people been on Emgality when they have Thinking abnormal? *

What is the gender of people who have Thinking abnormal when taking Emgality? *

female: 90 %
male: 10 %

What is the age of people who have Thinking abnormal when taking Emgality? *

What are other drugs people take besides Emgality? *

What are other side effects people have besides Thinking abnormal? *

Migraine (headache): 9 people, 28.12%
Stress And Anxiety: 8 people, 25.00%
Feeling Abnormal: 8 people, 25.00%
Headache (pain in head): 7 people, 21.88%
Nausea (feeling of having an urge to vomit): 6 people, 18.75%
Injection Site Pain: 5 people, 15.62%
Insomnia (sleeplessness): 4 people, 12.50%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 12.50%
Nausea And Vomiting: 3 people, 9.38%
Hypersensitivity: 3 people, 9.38%

What are the existing conditions these people have? *

Migraine (headache): 16 people, 50.00%
Headache (pain in head): 4 people, 12.50%
Wheezing (a high-pitched whistling sound made while you breath): 1 person, 3.12%
Pain: 1 person, 3.12%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 3.12%
Migraine Without Aura (headache without neurological problems): 1 person, 3.12%
Dyspnea (difficult or laboured breathing): 1 person, 3.12%
Drowsiness: 1 person, 3.12%
Cluster Headache (one-sided head pain with tearing): 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Emgality and have Thinking abnormal?

- Check whether Thinking abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Emgality:

Emgality (24,702 reports)

Browse all side effects of Emgality:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thinking abnormal:

Thinking abnormal (1,087 drugs)

Browse all the conditions that are associated with Thinking abnormal:

Thinking abnormal (1,180 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on galcanezumab-gnlm (the active ingredients of Emgality) and Emgality (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.